The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 15, 2022

Filed:

Apr. 04, 2022
Applicant:

Chimera Bioengineering, Inc., Pacifica, CA (US);

Inventors:

Benjamin Wang, Menlo Park, CA (US);

Gusti Zeiner, Pacifica, CA (US);

Krista McNally, Foster City, CA (US);

Assignee:

Chimera Bioengineering, Inc., Pacifica, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/63 (2006.01); C12Q 1/54 (2006.01); A61K 35/17 (2015.01); C12N 15/85 (2006.01); C12N 15/62 (2006.01); C12N 15/113 (2010.01); C07K 16/18 (2006.01); C07K 14/195 (2006.01); A61P 35/00 (2006.01); C07K 14/52 (2006.01); C07K 14/82 (2006.01); A61K 38/20 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 38/208 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/195 (2013.01); C07K 14/52 (2013.01); C07K 14/7051 (2013.01); C07K 14/82 (2013.01); C07K 16/18 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2896 (2013.01); C12N 15/113 (2013.01); C12N 15/62 (2013.01); C12N 15/85 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01);
Abstract

Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.


Find Patent Forward Citations

Loading…